Category

Archives

CSF-1R

CSF-1R inhibitor, pexidartinib, sensitizes esophageal adenocarcinoma to PD-1 immune checkpoint blockade in a rat model

11 views | May 19 2022

Ashten N Omstead et al. showed limited toxicity with significant tumor shrinkage in pexidartinib treated animals compared to controls, single agent and in combination with a PD-1 inhibitor, AUNP-12. [Read the Full Post]

Pharmacological Depletion of Microglia Leads to a Dose-Dependent Reduction in Inflammation and Senescence in the Aged Murine Brain

22 views | Apr 11 2022

Milan R Stojiljkovic et al. found that increased and detrimental brain inflammation in aged murine brain could be impaired by selectively reducing the microglial cell population. [Read the Full Post]

The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder

89 views | Feb 21 2022

Robert Roskoski Jr thought that the FDA approval of erdafitinib for the treatment of urinary bladder cancers might stimulate additional work targeting the many other FGFR-driven neoplasms. [Read the Full Post]

Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial

0 views | Feb 08 2022

C Dinkic et al. found that Pazopanib 600mg daily p.o. and metronomic cyclophosphamide 50mg daily p.o. is a feasible regimen for patients with recurrent platinum-resistant EOC and showed promising activity in this previously treated patient population. [Read the Full Post]

Inhibiting microglia proliferation after spinal cord injury improves recovery in mice and nonhuman primates

187 views | Oct 18 2021

Gaëtan Poulen et al. found that a transient oral GW2580 treatment post-injury might provide a promising therapeutic strategy for SCI patients and might also be extended to other central nervous system disorders displaying microglia activation. [Read the Full Post]

IL-1β-induced Elevation of SLC7A11 Promotes Hepatocellular Carcinoma Metastasis through Upregulating PD-L1 and CSF1

192 views | Aug 19 2021

Qin He et al. found that IL-1β-induced SLC7A11 overexpression upregulated PD-L1 and CSF1 through αKG/HIF1α axis, which promoted TAMs and MDSCs infiltration. [Read the Full Post]

Suppression of Microgliosis With the Colony-Stimulating Factor 1 Receptor Inhibitor PLX3397 Does Not Attenuate Memory Defects During Epileptogenesis in the Rat

399 views | Jun 29 2021

Season K Wyatt-Johnson eal. revealed that PLX3397 did not improve or worsen the memory deficits in rats that sustained pilocarpine-induced SE. [Read the Full Post]

Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia

424 views | Jun 28 2021

Catherine C Smith et al. thought that Mutations in CCND3, a gene not commonly mutated in AML, were a novel cause of clinical primary resistance to FLT3 inhibitors in AML and might have sensitivity to CDK4/6 inhibition. [Read the Full Post]

IL33 (Interleukin 33)/ST2 (Interleukin 1 Receptor-Like 1) Axis Drives Protective Microglial Responses and Promotes White Matter Integrity After Stroke

167 views | May 03 2021

Di Xie et al. found that the IL33/ST2/STAT6 signaling as a potential immune regulatory mechanism to modulate microglia/macrophage activity, improved white matter integrity, and restored long-term neurological functions after stroke. [Read the Full Post]

Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma

248 views | Mar 03 2021

M -L Nairismägi found that the activity of PRN371 had a more durable inhibition on JAK3 compared to tofacitinib in vitro, leading to significant tumor growth inhibition in a NKTL xenograft model harboring JAK3 activating mutation. [Read the Full Post]